{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:20:35Z","timestamp":1787314835695,"version":"build-2736575974"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008967","name":"Philipps-Universit\u00e4t Marburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008967","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Minimal\/measurable residual disease (MRD) in Acute Myeloid Leukemia (AML) is defined as persistent leukemic cells below cytomorphological detection threshold. Next generation sequencing (NGS) of circulating cell-free DNA (cfDNA) to profile cancer-associated mutations has been shown to allow for quantification of disease burden in solid tumors and has also been suggested to enable minimally invasive follow-up of AML patients. In this pilot study we investigated the technical sensitivity and potential prognostic implications of cfDNA-based MRD monitoring in AML after allogeneic stem cell transplantation in comparison to donor chimerism analysis or, respectively, after consolidation chemotherapy. 75 cfDNA samples from 29 patients were analyzed by targeted NGS using a commercially available 10- or 37-gene hotspot panel (VariantPlex Core AML or Core Myeloid panel, ArcherDx). Patients\u2019 leukemias exhibited 1\u20137 mutations as determined by routine diagnostics. Only previously identified mutations were considered for MRD evaluation. cfDNA was isolated in sufficient amounts for NGS from all samples (total yield 24 ng\u20135.2\u00a0\u00b5g). The sensitivity of variant detection increased with higher overall read count and higher mutation-specific coverage (variant allele frequency [VAF] range 0.08\u2013100%). At least one previously known mutation was identified in 32\/55 samples (58%, VAF 0.08\u201378.04%) which were taken during hematological complete remission (CR) in both patients after allogeneic stem cell transplantation (aHSCT) and patients after consolidation chemotherapy. In patients after aHSCT (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200925), at least one previously known mutation was detected in 16\/29 cfDNA samples (55.1%, VAF 0.08\u20136.7%) obtained when donor chimerism was \u2265\u200990% and in 6\/6 samples (100%, VAF: 0.88\u201363.77%) with reduced donor chimerism. Probability of progression-free survival 17 months after aHSCT in patients with donor chimerism\u2009\u2265\u200990% but mutation-positive cfDNA was 64% compared to 100% in patients with undetectable MRD. In patients after consolidation chemotherapy, cfDNA was positive in all samples taken during CR (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20094; VAF 0.26\u201329.84%) and non-CR (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20094; VAF 8.46\u2013100%). Our results indicate that NGS of cfDNA is suitable for MRD monitoring in AML and offers higher sensitivity for detecting residual leukemic cells than chimerism analysis in patients after aHSCT. Further studies are needed to evaluate clinical relevance of MRD status as determined in cfDNA.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-20589-3","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T20:06:49Z","timestamp":1758658009000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Detection of minimal residual disease in circulating cell-free DNA in acute myeloid leukemia"],"prefix":"10.1038","volume":"15","author":[{"given":"Charlotte","family":"Sommer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildegard I. D.","family":"Mack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine C.","family":"Killer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Nist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Stiewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Neubauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Brendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth K. M.","family":"Mack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"20589_CR1","unstructured":"SEER Explorer. Acute Myeloid Leukemia (AML) Recent Trends in SEER Age-Adjusted Incidence Rates, 2000\u20132021 [Internet]. 2025. Available from: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/"},{"key":"20589_CR2","doi-asserted-by":"publisher","unstructured":"D\u00f6hner, H. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood\u00a0 140(12):1345\u201377. (2022). https:\/\/doi.org\/10.1182\/blood.2022016867","DOI":"10.1182\/blood.2022016867"},{"key":"20589_CR3","doi-asserted-by":"crossref","unstructured":"Papaemmanuil, E. et al. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 374(23):2209\u201321. (2016)","DOI":"10.1056\/NEJMoa1516192"},{"key":"20589_CR4","doi-asserted-by":"crossref","unstructured":"Ganzel, C. et al. Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling. Leuk. Res. 123:106971. (2022). https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0145212622003472","DOI":"10.1016\/j.leukres.2022.106971"},{"key":"20589_CR5","doi-asserted-by":"publisher","unstructured":"Hoffmann, J. C. et al. Monitoring of acute myeloid leukemia patients after allogeneic stem cell transplantation employing semi-automated CD34\u2009+\u2009donor cell chimerism analysis. Ann. Hematol. 93(2):279\u201385. (2014). https:\/\/doi.org\/10.1007\/s00277-013-1961-4","DOI":"10.1007\/s00277-013-1961-4"},{"key":"20589_CR6","doi-asserted-by":"crossref","unstructured":"Schuurhuis, G. J. et al. Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 131(12):1275\u201391 (2018). https:\/\/pubmed.ncbi.nlm.nih.gov\/29330221","DOI":"10.1182\/blood-2017-09-801498"},{"key":"20589_CR7","unstructured":"Mack, E. K. M. et al. Comprehensive genetic diagnosis of acute myeloid leukemia by next generation sequencing. Haematologica (2018). http:\/\/www.haematologica.org\/content\/early\/2018\/09\/03\/haematol.2018.194258.abstract"},{"key":"20589_CR8","doi-asserted-by":"crossref","unstructured":"Haferlach T. Advancing leukemia diagnostics: role of next generation sequencing (NGS) in acute myeloid leukemia. Hematol. Rep. 12, 2020.","DOI":"10.4081\/hr.2020.8957"},{"key":"20589_CR9","doi-asserted-by":"publisher","unstructured":"Gao, Y-J. et al. Increased integrity of circulating cell-free DNA in plasma of patients with acute leukemia. 48(11), 1651\u20136 (2010). https:\/\/doi.org\/10.1515\/CCLM.2010.311","DOI":"10.1515\/CCLM.2010.311"},{"issue":"6","key":"20589_CR10","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s00277-020-04008-3","volume":"99","author":"JY Hur","year":"2020","unstructured":"Hur, J. Y. et al. Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas. Ann. Hematol. 99(6), 1293\u2013302. https:\/\/doi.org\/10.1007\/s00277-020-04008-3 (2020).","journal-title":"Ann. Hematol."},{"key":"20589_CR11","doi-asserted-by":"publisher","unstructured":"Bettegowda, C. et al. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Sci. Transl. Med. 6(224):224ra24-224ra24 (2014). https:\/\/doi.org\/10.1126\/scitranslmed.3007094","DOI":"10.1126\/scitranslmed.3007094"},{"issue":"403","key":"20589_CR12","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1126\/scitranslmed.aan2415","volume":"9","author":"J Phallen","year":"2017","unstructured":"Phallen, J. et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci. Transl. Med. 9(403), 2415. https:\/\/doi.org\/10.1126\/scitranslmed.aan2415 (2017).","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"20589_CR13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41408-018-0111-6","volume":"8","author":"E Bohers","year":"2018","unstructured":"Bohers, E. et al. Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort. Blood Cancer J 8(8), 74. https:\/\/doi.org\/10.1038\/s41408-018-0111-6 (2018).","journal-title":"Blood Cancer J"},{"key":"20589_CR14","doi-asserted-by":"publisher","unstructured":"Yeh, P. et al. Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes. Blood 129(12):1685\u201390 (2017). https:\/\/doi.org\/10.1182\/blood-2016-09-740308","DOI":"10.1182\/blood-2016-09-740308"},{"key":"20589_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04771-5","author":"EKM Mack","year":"2022","unstructured":"Mack, E. K. M. et al. Monitoring multiple myeloma in the peripheral blood based on cell-free DNA and circulating plasma cells. Ann. Hematol. https:\/\/doi.org\/10.1007\/s00277-022-04771-5 (2022).","journal-title":"Ann. Hematol."},{"issue":"1","key":"20589_CR16","doi-asserted-by":"publisher","first-page":"5068","DOI":"10.1038\/s41467-018-07466-6","volume":"9","author":"J Moss","year":"2018","unstructured":"Moss, J. et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nat. Commun. 9(1), 5068. https:\/\/doi.org\/10.1038\/s41467-018-07466-6 (2018).","journal-title":"Nat. Commun."},{"key":"20589_CR17","doi-asserted-by":"crossref","unstructured":"Pasca, S. et al. Cell-free DNA measurable residual disease as a predictor of postallogeneic hematopoietic cell transplant outcomes. Blood Adv 7(16):4660\u201370 (2023). https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2473952923003002","DOI":"10.1182\/bloodadvances.2023010416"},{"key":"20589_CR18","doi-asserted-by":"crossref","unstructured":"Haber, D. A. & Velculescu, V. E. Blood-Based Analyses of Cancer: Circulating Tumor Cells and Circulating Tumor DNA. Cancer Discov 4(6):650 LP\u2013661. (2014). Available from: http:\/\/cancerdiscovery.aacrjournals.org\/content\/4\/6\/650.abstract","DOI":"10.1158\/2159-8290.CD-13-1014"},{"issue":"26","key":"20589_CR19","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser, M. et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood 138(26), 2753\u201367. https:\/\/doi.org\/10.1182\/blood.2021013626 (2021).","journal-title":"Blood"},{"issue":"8","key":"20589_CR20","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.jmoldx.2021.05.001","volume":"23","author":"C Rausch","year":"2021","unstructured":"Rausch, C. et al. Double drop-off droplet digital PCR: A novel, versatile tool for mutation screening and residual disease monitoring in acute myeloid leukemia using cellular or cell-free DNA. J Mol Diagnostics 23(8), 975\u201385. https:\/\/doi.org\/10.1016\/j.jmoldx.2021.05.001 (2021).","journal-title":"J Mol Diagnostics"},{"key":"20589_CR21","doi-asserted-by":"crossref","unstructured":"Waterhouse, M. et al. Monitoring of Measurable Residual Disease Using Circulating DNA after Allogeneic Hematopoietic Cell Transplantation. Vol. 14, Cancers. (2022).","DOI":"10.3390\/cancers14143307"},{"key":"20589_CR22","doi-asserted-by":"publisher","unstructured":"Horak, P. et al. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med. 24(5):986\u201398 (2022). https:\/\/doi.org\/10.1016\/j.gim.2022.01.001","DOI":"10.1016\/j.gim.2022.01.001"},{"key":"20589_CR23","doi-asserted-by":"publisher","unstructured":"Tate, J. G. et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 47(D1):D941\u20137 (2019). https:\/\/doi.org\/10.1093\/nar\/gky1015","DOI":"10.1093\/nar\/gky1015"},{"key":"20589_CR24","doi-asserted-by":"publisher","unstructured":"Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res.\u00a046(D1):D1062\u20137 (2018). https:\/\/doi.org\/10.1093\/nar\/gkx1153","DOI":"10.1093\/nar\/gkx1153"},{"key":"20589_CR25","doi-asserted-by":"publisher","unstructured":"Shihab, H. A. et al. Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden markov models. Hum. Mutat. 34(1), 57\u201365 (2013). https:\/\/doi.org\/10.1002\/humu.22225","DOI":"10.1002\/humu.22225"},{"key":"20589_CR26","doi-asserted-by":"publisher","unstructured":"Adzhubei, I., Jordan, D. M. & Sunyaev, S. R. Predicting Functional Effect of Human Missense Mutations Using PolyPhen-2. Curr. Protoc. Hum. Genet.\u00a076(1), 7.20.1\u20137.20.41 (2013). https:\/\/doi.org\/10.1002\/0471142905.hg0720s76","DOI":"10.1002\/0471142905.hg0720s76"},{"key":"20589_CR27","doi-asserted-by":"publisher","unstructured":"Choi, Y. & Chan, A. P. PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels. Bioinformatics 31(16), 2745\u20137 (2015). https:\/\/doi.org\/10.1093\/bioinformatics\/btv195","DOI":"10.1093\/bioinformatics\/btv195"},{"key":"20589_CR28","doi-asserted-by":"publisher","unstructured":"Ng, P. C. & Henikoff, S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res. 31(13):3812\u20134 (2003). https:\/\/doi.org\/10.1093\/nar\/gkg509","DOI":"10.1093\/nar\/gkg509"},{"key":"20589_CR29","doi-asserted-by":"publisher","unstructured":"Thiede, C. et al. Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers. Leukemia 15(2), 293\u2013302 (2001). https:\/\/doi.org\/10.1038\/sj.leu.2401953","DOI":"10.1038\/sj.leu.2401953"},{"key":"20589_CR30","doi-asserted-by":"crossref","unstructured":"Short, N. J. & Ravandi, F. How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia? Haematologica 104(8), 1532\u201341. (2019). https:\/\/haematologica.org\/article\/view\/9001","DOI":"10.3324\/haematol.2018.208454"},{"key":"20589_CR31","doi-asserted-by":"publisher","unstructured":"Short, N. J. et al. Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis. Leukemia 36(12), 2817\u201326 (2022). https:\/\/doi.org\/10.1038\/s41375-022-01692-0","DOI":"10.1038\/s41375-022-01692-0"},{"issue":"25","key":"20589_CR32","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1182\/blood-2018-10-880690","volume":"133","author":"S Nakamura","year":"2019","unstructured":"Nakamura, S. et al. Prognostic impact of circulating tumor DNA status post\u2013allogeneic hematopoietic stem cell transplantation in AML and MDS. Blood 133(25), 2682\u201395. https:\/\/doi.org\/10.1182\/blood-2018-10-880690 (2019).","journal-title":"Blood"},{"key":"20589_CR33","doi-asserted-by":"publisher","unstructured":"Zhou, X. et al. Serial monitoring of circulating tumour DNA on clinical outcome in myelodysplastic syndromes and acute myeloid leukaemia. Clin. Transl. Med. 13(7):e1349. (2023). https:\/\/doi.org\/10.1002\/ctm2.1349","DOI":"10.1002\/ctm2.1349"},{"key":"20589_CR34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/cancers14246121","volume":"14","author":"J-M Lee","year":"2022","unstructured":"Lee, J.-M. et al. FLT3-ITD measurable residual disease monitoring in acute myeloid leukemia using next-generation sequencing. Cancers. 14, 8 (2022).","journal-title":"Cancers."},{"key":"20589_CR35","doi-asserted-by":"publisher","unstructured":"Grob, T. et al. Prognostic value of FLT3-internal tandem duplication residual disease in acute myeloid leukemia. J. Clin. Oncol.\u00a041(4), 756\u201365 (2022). https:\/\/doi.org\/10.1200\/JCO.22.00715","DOI":"10.1200\/JCO.22.00715"},{"key":"20589_CR36","doi-asserted-by":"publisher","unstructured":"R\u00fccker, F. G. et al. Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin. Blood Adv.\u00a08(23), 6067\u201380 (2024). https:\/\/doi.org\/10.1182\/bloodadvances.2024013758","DOI":"10.1182\/bloodadvances.2024013758"},{"key":"20589_CR37","unstructured":"Stone, R. M. et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N. Engl. J. Med. 377(5), 454\u201364. (2017). Available from: http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5754190\/"},{"issue":"10388","key":"20589_CR38","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba, H. P. et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401(10388), 1571\u201383. https:\/\/doi.org\/10.1016\/S0140-6736(23)00464-6 (2023).","journal-title":"Lancet"},{"key":"20589_CR39","doi-asserted-by":"publisher","unstructured":"Adam, I. et al. Assessment of minimal residual disease in standard-risk AML. N. Engl. J. Med.\u00a0374(5), 422\u201333. (2025). https:\/\/doi.org\/10.1056\/NEJMoa1507471","DOI":"10.1056\/NEJMoa1507471"},{"key":"20589_CR40","doi-asserted-by":"crossref","unstructured":"Short, N. J. et al. Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. Blood Adv. 4(8), 1670\u20137. (2020). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32324887","DOI":"10.1182\/bloodadvances.2019001156"},{"issue":"1","key":"20589_CR41","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41408-024-01078-8","volume":"14","author":"P Hirsch","year":"2024","unstructured":"Hirsch, P. et al. Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study. Blood Cancer J 14(1), 97. https:\/\/doi.org\/10.1038\/s41408-024-01078-8 (2024).","journal-title":"Blood Cancer J"},{"key":"20589_CR42","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1158\/1538-7445.AM2019-1699","volume":"79","author":"V Johnson","year":"2019","unstructured":"Johnson, V. et al. Abstract 1699: accurate detection of low AF variants relevant to AML by anchored multiplex PCR and next generation sequencing. Cancer Res. 79, 1699 (2019).","journal-title":"Cancer Res."},{"issue":"10","key":"20589_CR43","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1038\/s41375-019-0483-z","volume":"33","author":"TJ Bl\u00e4tte","year":"2019","unstructured":"Bl\u00e4tte, T. J. et al. getITD for FLT3-ITD-based MRD monitoring in AML. Leukemia 33(10), 2535\u20139. https:\/\/doi.org\/10.1038\/s41375-019-0483-z (2019).","journal-title":"Leukemia"},{"key":"20589_CR44","doi-asserted-by":"publisher","unstructured":"Pettersson, L. et al. Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemia. Int. J. Lab. Hematol.\u00a043(4), 664\u201374. (2021). https:\/\/doi.org\/10.1111\/ijlh.13608","DOI":"10.1111\/ijlh.13608"},{"key":"20589_CR45","doi-asserted-by":"publisher","unstructured":"Ruan, M. et al. Targeted next-generation sequencing of circulating tumor DNA, bone marrow, and peripheral blood mononuclear cells in pediatric AML. Front. Oncol. 11 (2021). Available from: https:\/\/www.frontiersin.org\/journals\/oncology\/articles\/https:\/\/doi.org\/10.3389\/fonc.2021.666470","DOI":"10.3389\/fonc.2021.666470"},{"key":"20589_CR46","doi-asserted-by":"publisher","unstructured":"Hupe, H. C. et al. Cell-free DNA for detection and monitoring of extramedullary AML relapse. HemaSphere 9(3), e70097 (2025). https:\/\/doi.org\/10.1002\/hem3.70097","DOI":"10.1002\/hem3.70097"},{"key":"20589_CR47","unstructured":"Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med . 371(26), 2488\u201398 (2014). https:\/\/pubmed.ncbi.nlm.nih.gov\/25426837"},{"key":"20589_CR48","doi-asserted-by":"publisher","unstructured":"Jongen-Lavrencic, M. et al. Molecular Minimal Residual Disease in Acute Myeloid Leukemia. N. Engl. J. Med. 378(13), 1189\u201399 (2018). https:\/\/doi.org\/10.1056\/NEJMoa1716863","DOI":"10.1056\/NEJMoa1716863"},{"issue":"7","key":"20589_CR49","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/s41375-018-0034-z","volume":"32","author":"M Rothenberg-Thurley","year":"2018","unstructured":"Rothenberg-Thurley, M. et al. Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia. Leukemia 32(7), 1598\u2013608. https:\/\/doi.org\/10.1038\/s41375-018-0034-z (2018).","journal-title":"Leukemia"},{"key":"20589_CR50","doi-asserted-by":"publisher","unstructured":"Kim, H-J. et al. Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia. Blood Cancer J. 11(6), 109 (2021). https:\/\/doi.org\/10.1038\/s41408-021-00500-9","DOI":"10.1038\/s41408-021-00500-9"},{"issue":"1","key":"20589_CR51","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41375-023-02072-y","volume":"38","author":"L Bischof","year":"2024","unstructured":"Bischof, L. et al. Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation. Leukemia 38(1), 198\u2013201. https:\/\/doi.org\/10.1038\/s41375-023-02072-y (2024).","journal-title":"Leukemia"},{"key":"20589_CR52","doi-asserted-by":"crossref","unstructured":"Pettersson, L. et al. Development and performance of a next generation sequencing (NGS) assay for monitoring of mixed chimerism. Clin. Chim. Acta [Internet]. 512, 40\u20138. (2021). Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0009898120305167","DOI":"10.1016\/j.cca.2020.10.034"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20589-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20589-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20589-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T20:06:52Z","timestamp":1758658012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20589-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["20589"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-20589-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32679"}}